NCT05320575View on ClinicalTrials.gov

Zanubrutinib for HLH

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2023

Conditions
HLH
Interventions
DRUG

Zanubrutinib

The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.

Trial Locations (1)

Unknown

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Friendship Hospital

OTHER